Ventyx Investment Portfolios

Stocks
Oppenheimer Affirms Outperform Rating for Ventyx Biosciences Nov 8, 2024
Pharmaceuticals
Ventyx Biosciences Faces Setback as Crohn's Disease Drug Candidate VTX958 Fails Phase 2 Trial Jul 29, 2024